← March 11, 2026 briefingHealth
Wegovy Linked to Five Times Greater Sudden Sight Loss Risk
A large-scale study has found that patients taking Wegovy face nearly five times the risk of sudden sight loss compared to those on Ozempic, despite both drugs containing the same active ingredient, semaglutide, at different doses. The condition, known as an "eye stroke," reduces blood flow to the optic nerve and is believed to be a dose-related side effect. The finding adds a serious new safety concern to the blockbuster class of weight-loss and diabetes drugs already used by tens of millions worldwide.
Sources
